Journal
CANCER LETTERS
Volume 378, Issue 2, Pages 69-79Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.05.004
Keywords
Histone methyltransferase; NSD2; Tamoxifen resistance; Pentose phosphate pathway; Metabolism
Categories
Funding
- NIH [DK060019, CA206222, CA150197]
- National Natural Science Foundation of China [81373655]
- Natural Science Foundation of Guangdong Province, China [2013B021800226]
- Manitoba Breast Tumor Bank, Canadian Tumor Repository Network - CancerCare Manitoba Foundation (CCMF)
- Canadian Institutes of Health Research (CIHR) [PRG80155]
- CDMRP [893261, CA150197] Funding Source: Federal RePORTER
Ask authors/readers for more resources
Metabolic reprogramming such as the aerobic glycolysis or Warburg effect is well recognized as a common feature of tumorigenesis. However, molecular mechanisms underlying metabolic alterations for tumor therapeutic resistance are poorly understood. Through gene expression profiling analysis we found that histone H3K36 methyltransferase NSD2/MMSET/WHSC1 expression was highly elevated in tamoxifen-resistant breast cancer cell lines and clinical tumors. IHC analysis indicated that NSD2 protein overexpression was associated with the disease recurrence and poor survival. Ectopic expression of NSD2 wild type, but not the methylase-defective mutant, drove endocrine resistance in multiple cell models and xenograft tumors. Mechanistically, NSD2 was recruited to and methylated H3K36me2 at the promoters of key glucose metabolic enzyme genes. Its overexpression coordinately up-regulated hexokinase 2 (HK2) and glucose 6-phosphate dehydrogenase (G6PD), two key enzymes of glycolysis and the pentose phosphate pathway (PPP), as well as TP53-induced glycolysis regulatory phosphatase TIGAR. Consequently, NSD2-driven tamoxifen-resistant cells and tumors displayed heightened PPP activity, elevated NADPH production, and reduced ROS level, without significantly altered glycolysis. These results illustrate a coordinated, epigenetic activation of key glucose metabolic enzymes in therapeutic resistance and nominate methyltransferase NSD2 as a potential therapeutic target for endocrine resistant breast cancer. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available